PIK3CD and acute lymphoblastic leukemia: Taken together, these findings indicated that longitudinal inhibition at two nodes of the PI3K/Akt/mTOR network with NVP-BEZ235, either alone or in combination with chemotherapeutic drugs, may be an efficient treatment of those T-ALL cases that have aberrant upregulation of this signaling pathway [239].